Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2022 can now access the abstract booklet, e-posters and videos, the poster carousel, and more via My ENETS.

ENETS Abstract Search

#3003 The Proinflammatory Molecule, VAP-1, Is Enriched in the Stroma of Midgut NETs and Plaques of Carcinoid Heart Disease Valves

Introduction: Vascular adhesion protein-1 (VAP-1) is a novel driver of tissue inflammation and fibrosis.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Shah T, Sagar V, Neil D, Liu B, Barriuso J,

Keywords: carcinoid, GEP-NET, VAP-1, ECM, tumour stroma, biomarker,

#3002 Quality of Life, Tumour Heterogeneity and Biomarker Levels in Patients with Progressive Pancreatic or Midgut Neuroendocrine Tumours: Baseline Data from CLARINET FORTE

Introduction: Lanreotide autogel (LAN) 120 mg every (q)28 days (standard regimen) improves progression-free survival vs placebo in patients with advanced, somatostatin receptor-positive (SSTR+) gastroenteropancreatic neuroendocrine tumours (NETs).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Ruszniewski P, Ćwikła J, Lombard-Bohas C, Borbath I, Shah T,

Keywords: Neuroendocrine tumours, lanreotide,

#2997 Benefits of 177Lu-DOTATATE in Patients with Advanced Neuroendocrine Tumours: Case Reports from Two Patients with High Disease Burden

Introduction: In the NETTER-1 study, peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE increased progression-free survival (PFS) and time to deterioration in quality of life (QoL) in patients with advanced midgut neuroendocrine tumours (NETs), compared with octreotide.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Wadsley J, Shah T,

Keywords: 177Lu-DOTATATE, metastases, quality of life,

#2971 A Retrospective Multicentre Evaluation of the Outcomes and Management of Carcinoid Heart Disease in Patients with Advanced Midgut NETs: A NET-CONNECT Descriptive Study

Introduction: Carcinoid heart disease (CHD) is a poor prognostic factor in neuroendocrine tumours (NETs). However, the extreme variability of diagnostic and treatment approaches reported in literature account for uncertainties on the best management in this selected population.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Spada F

Authors: Spada F, Laskaratos F, Crona J, Oleinikov K, Zandee W,

Keywords: Carcinoid Heart Disease, NETs, Carcinoid Syndrome, Midgut NETs,

#2967 Longitudinal Changes in Plasma 5-Hydroxyindoleacetic Acid (5-HIAA) and Other Biomarkers during Treatment of Functional Midgut Neuroendocrine Tumours (NETs) with Lanreotide Autogel: CALM NET Study Results

Introduction: CALM-NET (EudraCT 2013-002194-22; NCT02075606) evaluated pre-treatment circulating tumour cell levels in patients with NETs as a predictor of response to lanreotide autogel (LAN).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Shah T, Caplin M, Khan M, Houchard A, Furnace M,

Keywords: neuroendocrine tumours, lanreotide, biomarkers,

Abstract Submissions in 2023

Abstract submissions for 2023 will open in September 2022!

 

The 20th Annual ENETS Conference in 2023 will provide the principal platform for NET researchers around the world to present their latest findings. ENETS will select the best abstracts submitted in both clinical and basic science and present these in sessions within the framework of its scientific programme.

 

Participants of the ENETS Conferences in 2022 can now access the abstract booklet, e-posters and videos, the poster carousel, and more via My ENETS.

Membership matters

Multidisciplinary is our credo. We welcome all NET-related disciplines and professionals! Learn more about the benefits of becoming an ENETS member.